Avidity Biosciences Inc has a consensus price target of $41.9, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Chardan Capital, and Needham on March 14, 2024, March 5, 2024, and March 4, 2024. With an average price target of $42.67 between Cantor Fitzgerald, Chardan Capital, and Needham, there's an implied 67.19% upside for Avidity Biosciences Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/14/2024 | RNA | Buy Now | Avidity Biosciences | $25.52 | 135.11% | Cantor Fitzgerald | Eric Schmidt | → $60 | Initiates | → Overweight | Get Alert |
03/05/2024 | RNA | Buy Now | Avidity Biosciences | $25.52 | 29.31% | Chardan Capital | Keay Nakae | $23 → $33 | Maintains | Buy | Get Alert |
03/04/2024 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
02/29/2024 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
02/29/2024 | RNA | Buy Now | Avidity Biosciences | $25.52 | -9.87% | Chardan Capital | Keay Nakae | → $23 | Reiterates | Buy → Buy | Get Alert |
01/03/2024 | RNA | Buy Now | Avidity Biosciences | $25.52 | 95.92% | Wells Fargo | Yanan Zhu | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
11/29/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 17.55% | Credit Suisse | Judah Frommer | → $30 | Reiterates | Outperform → Outperform | Get Alert |
08/09/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | -9.87% | Chardan Capital | Keay Nakae | $27 → $23 | Maintains | Buy | Get Alert |
08/09/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
05/22/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | -21.63% | Evercore ISI Group | Josh Schimmer | → $20 | Upgrade | In-Line → Outperform | Get Alert |
05/17/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
05/11/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 95.92% | Wells Fargo | Yanan Zhu | $55 → $50 | Maintains | Overweight | Get Alert |
05/10/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 17.55% | Credit Suisse | Judah Frommer | → $30 | Reiterates | → Outperform | Get Alert |
04/28/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Needham | Joseph Stringer | → $35 | Reiterates | → Buy | Get Alert |
03/31/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 17.55% | Credit Suisse | Judah Frommer | $35 → $30 | Maintains | Outperform | Get Alert |
03/31/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | -21.63% | Evercore ISI Group | Joshua Schimmer | → $20 | Downgrade | Outperform → In-Line | Get Alert |
03/31/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 5.8% | Chardan Capital | Keay Nakae | → $27 | Reiterates | → Buy | Get Alert |
03/01/2023 | RNA | Buy Now | Avidity Biosciences | $25.52 | 37.15% | Credit Suisse | Judah Frommer | → $35 | Reiterates | → Outperform | Get Alert |
The latest price target for Avidity Biosciences (NASDAQ: RNA) was reported by Cantor Fitzgerald on March 14, 2024. The analyst firm set a price target for $60.00 expecting RNA to rise to within 12 months (a possible 135.11% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Avidity Biosciences (NASDAQ: RNA) was provided by Cantor Fitzgerald, and Avidity Biosciences initiated their overweight rating.
The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.
The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a initiated with a price target of $0.00 to $60.00. The current price Avidity Biosciences (RNA) is trading at is $25.52, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.